CCA
ODT

Catalyst Capital Advisors’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Catalyst Capital Advisors’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-215
Closed -$5K – 583
2017
Q4 		$5K Buy
+215
New +$5.08K ﹤0.01% 398

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Catalyst Capital Advisors's ODT Position: Q1 2018 in Review

Catalyst Capital Advisors sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2018, closing a stake of 215 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in ODT in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 45 funds tracked by Wall St. Rank hold ODT as of Q1 2018.

  • Catalyst Capital Advisors reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 215 Odonate Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $5K.
  • Catalyst Capital Advisors first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Catalyst Capital Advisors's Odonate Therapeutics, Inc. Common Stock position peaked at $5K in Q4 2017.
  • 45 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Catalyst Capital Advisors's 13F filing for Q1 2018, filed 18 May 2018.